Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if long acting tolterodine confers more benefit
than intravaginal low dose estrogen in the treatment of Overactive Bladder Syndrome at 12
weeks post-treatment initiation. The hypothesis is that low dose intra-vaginal estrogen
confers greater benefit than tolterodine in the treatment of Overactive Bladder symptoms.
Secondary outcomes were to assess if the addition of the other therapy to the treatment
regimen conferred benefit at 24 weeks and 52 weeks.